Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia  by Foley, Samantha B. et al.
Cell Reports
ReportExpression of BCR/ABL p210 from a Knockin Allele
Enhances Bone Marrow Engraftment
without Inducing Neoplasia
Samantha B. Foley,1,3 Zacariah L. Hildenbrand,1,3 Abigail A. Soyombo,1 Jeffery A. Magee,1,4 Yipin Wu,1
Katherine I. Oravecz-Wilson,2 and Theodora S. Ross1,2,*
1Department of Internal Medicine and Cancer Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
2Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
3These authors contributed equally to this work
4Present address: Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA
*Correspondence: theo.ross@utsouthwestern.edu
http://dx.doi.org/10.1016/j.celrep.2013.08.037
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works
License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are
credited.SUMMARY
Chronic myeloid leukemia (CML) and some acute
lymphoblastic leukemias are characterized by the
t(9;22) chromosome, which encodes the BCR/ABL
oncogene. Multiple mouse models of CML express
BCR/ABL at high levels from non-Bcr promoters, re-
sulting in the development of leukemias. In contrast,
a significant fraction of healthy humans have been
found to have BCR/ABL-positive hematopoietic
cells. To bridge the gap between the information
derived from current mouse models and nonleuke-
mic humans with the BCR/ABL oncogene, we gener-
ated a knockin model with BCR/ABL p210 expressed
from the Bcr locus. Unlike previous models, expres-
sion of BCR/ABL from the knockin allele did not
induce leukemia. BCR/ABL mutant cells did exhibit
favorable bone marrow engraftment compared to
control cells. These data suggest that BCR/ABL
expression alone is insufficient to induce disease.
This model allows for inducible spatial and temporal
control of BCR/ABL expression for analysis of early
steps in the pathogenesis of BCR/ABL-expressing
leukemias.
INTRODUCTION
The molecular hallmark of chronic myeloid leukemia (CML) is the
BCR/ABL-expressing t(9;22) Philadelphia chromosome (Groffen
et al., 1984; Rowley, 1973; Rudkin et al., 1964). The discovery of
this mutation led to the development of tyrosine kinase inhibitors
(Druker et al., 2001a, 2001b; Kantarjian et al., 2002, 2006, 2010;
Talpaz et al., 2006) that are now the standard of care for patients
with CML (Ernst and Hochhaus, 2012; Zhang and Rowley, 2011).
BCR/ABL is believed to be sufficient for disease development,
as expression of BCR/ABL in mouse models leads to rapiddevelopment of hematopoietic neoplasias (Daley et al., 1990;
Elefanty et al., 1990; Honda and Hirai, 2001; Honda et al.,
1998; Huettner et al., 2003; Jaiswal et al., 2003; Kelliher et al.,
1990; Koschmieder et al., 2005; Voncken et al., 1995; Wong
and Witte, 2001). The current understanding of BCR/ABL-
induced disease stems from several experimental settings,
including the injection of cell lines or primary cells from CML
patients into immune-deficient mice, transduction of bone-
marrow-derived cells with retroviruses that express BCR/ABL
(Daley et al., 1990; Elefanty et al., 1990; Kelliher et al., 1990;
Wong and Witte, 2001), and expression of BCR/ABL in trans-
genic mice (Honda and Hirai, 2001; Honda et al., 1998; Huettner
et al., 2003; Jaiswal et al., 2003; Koschmieder et al., 2005;
Voncken et al., 1995). All of these mice express BCR/ABL from
active promoters and multiple copies of the oncogene.
Although data from these mouse models suggest that BCR/
ABL is sufficient to induce leukemia, some reports have indi-
cated that only high levels of BCR/ABL induce disease in
humans (Barnes et al., 2005; Gaiger et al., 1995). On the other
hand, low levels of BCR/ABL expression have been linked to
persistence of CML in the presence of tyrosine kinase inhibitors,
such as imatinib, due to a lack of oncogene dependency (Kumari
et al., 2012). Thus, extremes of oncogene expression may
contribute to our inability to eradicate CML. To address whether
a single copy of the BCR/ABL oncogene when expressed
from the endogenous locus leads to disease development and
persistence, we constructed a knockin model with expression
of human BCR/ABL p210 from the mouse Bcr locus. This model
has allowed us to determine whether expression of BCR/ABL as
a single-copy allele is sufficient to induce neoplasia.
RESULTS
To assess the role of a single copy of the BCR/ABL oncogene in
disease pathogenesis and to avoid reported embryonic lethality
(Castellanos et al., 1997; Heisterkamp et al., 1991), we generated
a conditional knockin allele of BCR/ABL. A loxP-bracketed tran-
scriptional stop cassette was engineered upstream of the humanCell Reports 5, 51–60, October 17, 2013 ª2013 The Authors 51
Figure 1. Conditional Knockin of BCR/ABL into the Murine Bcr Locus
(A) Schematic of the first seven of 23 exons of the murine Bcr genomic locus (Bcr+), the targeted BcrLSL-BCR/ABL knockin allele generated by homologous
recombination, and the allele with the deleted stop cassette (BcrBCR/ABL) following Cre-mediated recombination. The following features are indicated: stop
cassette bracketed by loxP recombination sequences (LSL), human BCR/ABL-ires-GFP cDNA, and genomic hybridization probes. See Figure S1for details of
vector construction.
(B) Southern blot analysis using 50, 30, and neo probes of SpeI-digested DNA from ESC clones showing the wild-type (WT)Bcr andmutant knockin alleles. Lane 1:
WT Bcr; lanes 2 and 3: Bcr+/LSL-BCR/ABL clones that were used to generate two different targeted lines of mice.
(C) Bcr message levels were significantly diminished in the spleens of Cre-negative heterozygous Bcr+/LSL-BCR/ABL adult mice (denoted Creneg;B/A). *p < 0.05.
Error bars denote SEM.
(D) Bcr and ABL polyclonal antibodies were used to detect endogenous mouse proteins in brain extracts from Cre-negative Bcr+/LSL-BCR/ABL and WT mice as
indicated. Lanes 1 and 2 are from WT mice, and lanes 3 and 4 are from knockin mice.
(legend continued on next page)
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BCR/ABL p210-IRES-GFP cDNA (Pear et al., 1998) in exon 1 of
the murine Bcr locus (BcrLSL-BCR/ABL; Figures 1A and S1A). This
conditional knockin allele allowed us to use different Cre trans-
genic mice to drive temporal and tissue-specific expression in
concert with the endogenous mouse promoter and the remain-
ing regulatory elements of the locus. C57BL/6 embryonic stem
cells (ESCs) were electroporated and screened for targeted
knockin alleles, and two ESC lines generated mice carrying the
BcrLSL-BCR/ABL mutation (Figures 1B and S1B). The C57BL/6
background has been used previously to induce disease in other
BCR/ABL mouse models, and this background can be readily
followed for donor chimerism following bone marrow trans-
plantation using CD45.1 and CD45.2 variants. Furthermore, we
sequenced the knockin allele from two different genomic
Bcr+/LSL-BCR/ABL spleens to confirm the absence of de novo
mutations in the BCR/ABL sequence. Bcr+/LSL-BCR/ABL mice
were born at predicted Mendelian frequency and displayed
normal growth. Lack of expression of wild-type Bcr from the
knockin locus resulted in Bcr haploinsufficiency reflected in
reduced Bcr message (Figure 1C) and protein (Figure 1D).
To express BCR/ABL from this knockin allele, we crossed the
Bcr+/LSL-BCR/ABL mice with Vav-Cre and Mx1-Cre transgenic
mice. The Vav- and interferon (pIpC)-induced Mx1 promoters
are specifically activated in embryonic (Georgiades et al.,
2002) and adult hematopoietic tissues, including hematopoietic
stem cells (HSCs) (Georgiades et al., 2002; Rajewsky et al.,
1996). Mx1-Cre- and Vav-Cre-mediated recombination and
BCR/ABL expression were predicted to emulate BCR/ABL
expression in CML patients because not only is Cre expression
restricted to hematopoietic tissues but also the knocked-in
BCR/ABL expression is further constrained by the endogenous
regulatory elements of the Bcr locus. We detected expression
of GFP by flow cytometry of peripheral blood in white blood cells
(WBCs) using either Vav-Cre- or Mx1-Cre-mediated recombina-
tion (Figure 1E; data not shown). Peripheral blood GFP levels
were highest in the Mac1+Gr1+ population (Figure S1C), and
GFP expression in bonemarrowwas highest in the stem/progen-
itor LSK (LinSca+;c-Kit+) population (Figures 1F and S1D).
Since Bcr is expressed primarily in hematopoietic stem and pro-
genitor cells (Wetzler et al., 1993), high GFP expression in HSCs
was expected. These BCR/ABL expression patterns are also
consistent with previous findings of enriched BCR/ABL expres-
sion in human bone marrow progenitors from CML patients
(Marega et al., 2010). Additionally, GFP and constitutively phos-
phorylated BCR/ABL were detected by western blot of whole
spleen extracts (Figures 1E, inset, and 1G). We tested for consti-(E) Vav-Cre expression in the hematopoietic system leads to recombination of
Creneg;B/A, and Vav-Cre;B/A mice were bled at 6 weeks of age, and WBCs were
significantly higher in the Vav-Cre;B/Amice (p < 0.0001). GFPwas quantified as th
relative to a WT baseline (denoted GFP(% of WBCs)). Inset: Mouse spleen extrac
three Creneg;B/A mice, and lanes 4–6 are from three Vav-Cre;B/A mice.
(F) Representative fluorescence-activated cell sorting plot of GFP expression in bo
(left) or Vav-Cre;B/A (right) mice. The majority (80%) of LSK cells from Vav-Cre;B/
The WT LSK cells were almost all GFP negative (purple).
(G) Immunoprecipitation and western blot analysis of spleen extracts from Vav-C
ABL (4G10). Lanes 1 and 3 are extracts fromWT spleens, and lanes 2 and 4 are e
1–3 that migrates just above the 150 kDa marker is not known.
See also Figure S1.tutive phosphorylation of CRKL and STAT5 in isolated LSK cells,
but did not observe phosphorylation (data not shown). These
data indicate that the knockin allele is expressed in a cellular
pattern similar to that of the Bcr protein and the expressed onco-
gene has the expected constitutive tyrosine kinase activity.
However, the amount of signaling is not strong enough for us
to detect phosphorylation of its downstream targets.
To determine whether the levels of BCR/ABL were similar to
the human situation in which BCR/ABL is expressed from
the human BCR locus, we compared the copy number of the
knocked-in BCR/ABL message with the copy number of the
mouse Bcrmessage in Vav-Cre;Bcr+/BCR-ABL mice. Using quan-
titative PCR (qPCR) and a huBCR/ABL-mBcr chimeric standard,
we measured the absolute levels of the splenic huBCR/ABL
message (8 copies/ng RNA; range 2–15; n = 13) and the mouse
Bcr message (13 copies/ng RNA; range 3–15; n = 10) in
Vav-Cre;BCR/ABL knockin mice. The numbers of BCR/ABL
and Bcr copies were of the same order of magnitude, although,
as expected, Bcr was higher. We did not expect the BCR/
ABL:Bcr ratio to be 1:1, as Vav-Cre does not induce 100%
recombination and is not expressed in every cell of the spleen.
These data, together with specific GFP expression in stem and
progenitor cells (Figure 1F), indicate that regulated expression
of the BCR/ABL knockin allele is similar to that of the endoge-
nous Bcr.
During the first year of observation of cohorts that were
of either Creneg;Bcr+/LSL-BCR/ABL, Vav-Cre;Bcr+/LSL-BCR/ABL
(n = 14) or pIpC-induced Mx1-Cre;Bcr+/LSL-BCR/ABL (n = 13)
genotypes, we saw no signs or symptoms of a hematopoietic
illness. Mice expressing BCR/ABL (Cre;Bcr+/LSL-BCR/ABL) had
normalWBCcounts (Figures2AandS2A) and theirWBCdifferen-
tials displayed normal myeloid and monocytic frequencies, with
only a slight trend of decreased lymphocyte frequencies (data
not shown). Over the 1.5 years of observation, Vav-Cre;
Bcr+/LSL-BCR/ABLmicewere sacrificed andnecropsied at 3-month
intervals (n = 3per timepoint). During this period, none of the Vav-
Cre;Bcr+/LSL-BCR/ABLmice orMx1-Cre;Bcr+/LSL-BCR/ABLmice dis-
played abnormalities at necropsy, and flow cytometry of bone
marrow showed normal stem and progenitor frequencies (Fig-
ure S2B andS2C). Furthermore, no changes in BCR/ABL expres-
sion were observed with age, as evidenced by steady peripheral
bloodGFP and spleen BCR/ABLmessage levels (Figures 2B and
2C). The bone marrow, spleen, and peripheral blood of a final set
of Vav-Cre;Bcr+/LSL-BCR/ABL mice sacrificed at 75 weeks of age
had normal HSC and early progenitor frequencies as well as
normalmyeloid and lymphoid progenitor frequencies (Figure 2D).the BcrLSL-BCR/ABL allele and GFP expression in peripheral blood WBCs. WT,
subjected to flow analysis for GFP fluorescence. The expression of GFP was
e percentage ofWBCs that exhibited a lateral shift in fluorescent signal intensity
ts were blotted with a GFP monoclonal antibody (Sigma). Lanes 1–3 are from
nemarrow stem and progenitor LSK (LinSca+c-Kit+) populations from control
A mice were GFP positive (green), compared with none (0.8%) in the WT mice.
re;B/A mice for expression and constitutive tyrosine phosphorylation of BCR/
xtracts from Vav-Cre;B/A spleens. The identity of the phospho-protein in lanes
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Spleen structure and histology as well as the frequency of
myeloid methylcellulose colonies (CFU-GEMM and CFU-GM)
from the final groups of Vav-Cre;B/A and Mx1-Cre;B/A
mice were normal (Figure 2E; data not shown). We observed
seven homozygous Vav-Cre;BcrLSL-BCR/ABL;LSL-BCR/ABL mice
(which have twice as much GFP as the heterozygous Vav-Cre;
Bcr+/LSL-BCR/ABL mice) for 10–12 months. All of these homozy-
gous mice remained disease free, indicating that two copies of
BCR/ABL are also not sufficient for disease development.
To determine whether the expression of BCR/ABL was neces-
sary for the survival of the cells expressing it, we treated Vav-
Cre;B/A mice with imatinib for 2 weeks and measured GFP in
peripheral blood. We detected no changes in GFP after imatinib
treatment, indicating that the majority of the BCR/ABL-express-
ing cells were not addicted to BCR/ABL (Figure S2D). This sup-
ports previous data indicating that leukemia cells that express
low levels of BCR/ABL do not undergo apoptosis when treated
with imatinib (Modi et al., 2007). These data are also consistent
with the hypothesis that low levels of BCR/ABL expression are
a reason for persistence of CML in patients treated with imatinib
(Kumari et al., 2012).
Although no hematopoietic abnormalities or addiction to BCR/
ABL expression were observed in the first year, a single
Vav-Cre;Bcr+/LSL-BCR/ABL knockin mouse spontaneously died at
58 weeks of age. At necropsy, this mouse was found to have
an effaced spleen with infiltration of neutrophils, mimicking
what is seen in the chronic phases of CML (Figure 2F). In addition
to this mouse, when the remaining members of this cohort were
sacrificed at 1.5 years of age, we observed a slight effacement of
the normal white/red pulp spleen structure in two out of the
remaining seven mice. However, the rest of the hematopoieticFigure 2. Phenotype of Vav-Cre;Bcr+/BCR/ABL Mice
(A) CBCs from WT (open circles) and BCR/ABL knockin (closed circles) mice wer
mice were observed for at least 1 year. Averages and SDs of WBCs counts of all
groups over the entire time course. Upon necropsy of a subset of the mice (n = 5
uncovered. Error bars denote SEM.
(B) BCR/ABL message in the spleen (left) and expression of GFP in the periphera
message was measured by absolute qPCR, and GFP fluorescence was measure
(C) BCR/ABL message levels in spleens (left) and GFP in peripheral blood (right)
(D) Final bone marrow (left) and spleen (right) progenitor frequencies in the cohor
Open circles represent aged control mice and closed circles represent aged Va
(Mac+Gr1+) frequencies were not altered in the presence of the BCR/ABL oncog
(E) Representative hematoxylin and eosin (H&E) stains of spleens from 1.5-year-
(F) Displayed are spleen H&E stains (top) of the one Vav-Cre;B/A mouse that succ
mouse (43magnification). Amyeloid infiltration was confirmed in the Vav-Cre;B/A
from the WT mouse was myeloperoxidase negative.
(G) Competitive bone marrow transplantation indicated that BCR/ABL enhances
(n = 3) donor mice (CD45.2) was mixed with an equal number of WT competitor
lethally irradiated recipients per donor (n = 45 recipients per genotype) in a CD45
marrow were assessed for donor chimerism by flow cytometry. The dotted line
Cre;Bcr+/BCR/ABL donor cells, and the solid line represents chimerism analysis in
CD45.2 on the y axis was expected to be 50% throughout the experiment. Res
cohort. The engraftment of the Vav-Cre;B/A cells was significantly from that of the
0.05; **p < 0.01; ***p < 0.001.
(H) Kaplan-Meier survival curve of Vav-Cre;B/A;A/E and Vav-Cre;B/A control mic
p < 0.01 (log rank test).
(I) CBCs from Vav-Cre;B/A;A/E knockin mice showed significant monocytosis and
Aml+/AML1/ETO (n = 14) mice were observed for 1 year. If a mouse died before the y
reported. Error bars denote SEM. *p < 0.05; ***p < 0.001.
See also Figure S2.analysis (bonemarrow, peripheral blood, and spleen flow cytom-
etry) of these two mice was normal. This single case of a myelo-
proliferative disease could be due either to expression of the
BCR/ABL oncogene or to the normal increased frequency of
myeloproliferation neoplasms that occurs with age in mice. In
fact, the presence of a single myeloproliferative neoplasm in
the BCR/ABL cohort was not significantly different from what
was observed in controls (p < 0.2).
Although expression of BCR/ABL from its endogenous
locus did not lead to disease, bone marrow cells from Vav-Cre;
Bcr+/LSL-BCR/ABL mice did exhibit an engraftment advantage
compared with wild-type bone marrow when the two were
cotransplanted into lethally irradiated mice (Figure 2G, dotted
line). It is possible that CD44 molecules on the BCR/ABL-
expressing stem cells in the knockin model are more functional
than CD44 of the cotransplanted wild-type cells. We considered
this possibility because of a recent report indicating that
BCR/ABL-expressing stem cells have a greater dependence
on CD44 for bone marrow engraftment compared with normal
stem cells (Krause et al., 2006). However, we did not observe
increased expression of CD44 in the BCR/ABL-expressing
stem and progenitor populations (data not shown). This
enhanced reconstitution could be a result of accumulation
of genetic mutations over time. Contrasting with the Cre-positive
cells, Cre-negative Bcr+/LSL-BCR/ABL haploinsufficient bone
marrow cells displayed a competitive disadvantage compared
with cotransplanted wild-type cells (Figure 2G, solid line). The
decreased engraftment by the Cre-negative Bcr+/LSL-BCR/ABL
bone marrow may be due to Bcr haploinsufficiency (Figure 1D).
Indeed, we found that the haploinsufficiency of Bcr in young
Cre-negative Bcr+/LSL-BCR/ABL mice (1–3 months of age) dide normal. Members of a cohort of WT (n = 9) and Vav-Cre;Bcr+/BCR/ABL (n = 15)
mice are reported. No significant differences were observed between the two
of each group) at 6 months and 1 year, no gross or histologic diseases were
l blood (right) of WT and Vav-Cre;B/A mice at 5 months of age. The BCR/ABL
d by flow cytometry as described in Figure 1E.
of WT and BCR/ABL mice at 11 months of age.
t of 1.5-year-old mice. All mice were without evidence of disease at necropsy.
v-Cre;B/A mice. HSC (LT-HSCs), B cell (B220), T cell (CD3), and myeloid cell
ene.
old control and Vav-Cre;B/A mice at 43 magnification.
umbed to a myeloproliferative neoplasm at 58 weeks of age and a WT control
spleen with myeloperoxidase staining (bottom; 103magnification). The spleen
engraftment. Bone marrow from Cre-negative B/A (n = 3) or Vav-Cre-positive
bone marrow (CD45.1) cells, and then 1 3 106 cells were transplanted into 15
.1:CD45.2 ratio of 1:1. At the indicated time points, peripheral blood and bone
represents the percentage of CD45.2 chimerism in mice that received Vav-
mice that received Cre-negative Bcr+/BCR/ABL donor cells. The percentage of
ults represent the average and SEM of the chimerism data from mice in each
Creneg;B/A cells at each time point (6, 10, or 16weeks posttransplantation); *p <
e. Vav-Cre;B/A;A/E mice were found dead or were sacrificed when moribund.
neutrophilia. Members of a cohort of control (n = 16) and Vav-Cre;Bcr+/BCR/ABL;
ear endpoint, the last available CBC data were included. Averages and SDs are
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lead to a decrease in the number of HSCs (Figure S2E). The fact
that expression of BCR/ABL overrode this negative engraftment
effect and provided an additional engraftment advantage (Fig-
ure 2G) may simply be due to the well-known constitutive prolif-
erative and survival signals from BCR/ABL that sustain CML in
humans (Cilloni and Saglio, 2012). Because we did not observe
increased frequencies of LT-HSCs in any of the Vav-Cre;BCR/
ABL mice, an engraftment advantage was likely not due
to BCR/ABL leading to increased self-renewal (Figure S2B).
Instead, BCR/ABL expression may provide a better environment
for cells to survive the normally harsh cytokine-poor state of an
irradiated bone marrow niche.
The infrequent occurrence of myeloproliferation after a long
latency in themice bearing the BCR/ABL knockin allele suggests
that additional genetic events are required for transformation of
hematopoietic cells. We previously observed this for the HIP1/
PDGFbR knockin allele (Oravecz-Wilson et al., 2009). To begin
to test this, we crossed the BCR/ABL mice with mice bearing a
conditional AML1/ETO knockin allele (Higuchi et al., 2002). Like
HIP1/PDGFbR and BCR/ABL, this AML1/ETO knockin allele on
its own is insufficient for leukemogenesis. Dual conditional
knockin mice with the Vav-Cre transgene were born at the ex-
pected Mendelian ratio and appeared healthy until spontaneous
deaths occurred in over 50% of the mice between 6 and
12 months of age (Figure 2H). Upon necropsy, we observed
splenic architecture effacement in mice whose spleens were
intact at death (Figure S2F). Prior to death, lymphopenia, throm-
bocytopenia, neutrophilia, and/or monocytosis were present in
the double-knockin mice (Figure 2I; data not shown). In the
mice that remained in this dual-knockin cohort, peripheral
blood GFP levels of the double-knockin mice (Vav-Cre;BCR/
ABL;AML1/ETO) were similar to those of the Vav-Cre;BCR/ABL
mice (Figure S2G, top panel). By the time of this last analysis
of GFP levels, all of the mice had aged enough to develop a
monocytosis (Figure S2G, bottom panel), which is the harbinger
of a lethal myeloproliferation (Figure 2H). There was one ‘‘outlier’’
mouse with a higher GFP level than the rest of the mice (14%
versus average of 5%). However, this level is similar to that found
in homozygous BCR/ABL mice (two copies of BCR/ABL) that do
not develop disease. These data indicate that a second hit (e.g.,
AML1/ETO), rather than an increased BCR/ABL level, is key
to the development of myeloproliferation in this mouse (Fig-
ure S2G). These data also indicate that even though AML1/
ETO has been found in many tyrosine-kinase-driven leukemias
(Golub et al., 1994; Miyoshi et al., 1991; Schessl et al., 2005)
and cooperates with BCR/ABL in these mice, the 5-month
latency to disease suggests that even more than two genetic
changes are needed for the development of BCR/ABL-associ-
ated leukemia.
Germline expression of transgenic BCR/ABL has been
reported to result in embryonic lethality (Heisterkamp et al.,
1991), and prior attempts to generate a germline knockin of
p190 BCR/ABL allele were not successful (Castellanos et al.,
1997). To determine when and why lethality occurs in embryo-
genesis, we crossed the Bcr+/LSL-BCR/ABL mice with transgenic
CMV-Cre mice to allow Cre recombination of the LoxP sites in
the germline (Schwenk et al., 1995). To our surprise, germline
expression of BCR/ABL in our mice was not embryonic lethal.56 Cell Reports 5, 51–60, October 17, 2013 ª2013 The AuthorsCMV-Cre;Bcr+/LSL-BCR/ABL mice were born at the predicted
Mendelian frequency and displayed no gross abnormalities.
Members of a cohort of these mice are now 1 year old and
show no evidence of cancer or other abnormalities. Although
CMV-Cre recombination leads to LoxP site recombination in all
cells of the body, the expression of the BCR/ABL knockin allele
also depends on many of the natural regulatory elements of the
Bcr locus. Thus, we predicted that the expression of BCR/ABL
would closely mimic that of Bcr (Heisterkamp et al., 1993).
Indeed, the BCR/ABL message (Figure 3A) was especially prev-
alent in the brain, in agreement with earlier reports that expres-
sion of Bcr protein is highest in the CNS (Heisterkamp et al.,
1993). Despite normal brain histology and size, the brains from
these mice had easily detectable BCR/ABL protein that ex-
hibited constitutively active tyrosine kinase activity (Figure 3B).
Expression of the knockin allele was also maintained in the
peripheral blood of these CMV-Cre; Bcr+/LSL-BCR/ABL mice at fre-
quencies similar to those observed in Vav-Cre;Bcr+/LSL-BCR/ABL
mice (Figure 3C). This CMV-Cre experiment further demon-
strates that this knockin allele mimics the tissue-specific expres-
sion pattern of the endogenous Bcr locus.
DISCUSSION
Although CML has been considered to exemplify a malignancy
caused by a single genetic event, three main lines of evidence
obtained prior to this report led us to question whether BCR/
ABL alone is responsible for inducing disease. First, blood cells
from up to 30% of healthy individuals repeatedly test positive
for the Philadelphia chromosome (Bayraktar and Goodman,
2010; Biernaux et al., 1995; Bose et al., 1998). Second, treatment
of patients with potent BCR/ABL inhibitors infrequently cures
their CML (Savona and Talpaz, 2008). Third, based on the low
copy number of BCR/ABL messages in residual diseased pro-
genitors from imatinib-treated CML patients, Kumari et al.
(2012) recently proposed that chronically low levels of BCR/
ABL in imatinib-refractory CML-initiating cells may be indepen-
dent of BCR/ABL signals for survival and explain their persis-
tence in the presence of imatinib. These data suggest that in
addition to the presence of the BCR/ABL oncogene, distinct
molecular changes may be required for disease onset, progres-
sion, and maintenance.
To address the challenges associated with current CML treat-
ments and to determinewhether single-gene-copy expression of
BCR/ABL is sufficient for CML development, we generated a
mouse model in which BCR/ABL p210 is expressed from the
endogenous Bcr locus. This allele allows for the expression of
the oncogene from its endogenous locus and mimics heterozy-
gous BCR knockout that occurs as a result of the translocation.
Although heterozygous Bcr knockout mice are grossly normal
(Voncken et al., 1995),Bcr haploinsufficiency has been proposed
to influencemyeloid leukemogenesis by the BCR/ABL oncogene
(Lin et al., 2001). In the latter study, Lin et al. (2001) evaluated the
acute phase of CML by injecting K562 cells into nonobese dia-
betic (NOD)/severe combined immunodeficiency (SCID) mice
under conditions in which endogenous BCR expression was
low, resulting in rapid development of disease in 100% of the
recipient mice. This 100% chance of disease development was
Figure 3. Germline BCR/ABL Expression Mimics that of BCR and
Does Not Alter the Health of Embryos, Newborns, or Mature Mice
(A) qPCR analysis for BCR/ABL RNA expression in CMV-Cre;B/A mouse
organs. Each assay was performed in triplicate and three mice were evaluated
(total assays n = 9). Brn, brain; Hrt, heart; Kdny, kidney; Lvr, liver; Lng, lung;
Mu, muscle; Spln, spleen.
(B) Immunoprecipitation and western blot analysis for BCR/ABL expression
and constitutive phosphorylation (4G10) in brain extracts from CMV-Cre;B/A
mice. The identity of the phosphoprotein that migrates just above the 150 kDa
marker in the right-hand panel is not known but serves as an internal loading
control. Lane 1: WT brain; lane 2: Creneg;B/A brain; lane 3: CMV-Cre;B/A brain.
(C) Peripheral blood cells of adult CMV-Cre;B/A mice have GFP-positive
WBCs similar to those observed in Vav-Cre;B/A mice. Error bars are SEM;
***p < 0.001; ****p < 0.0001.compared with a 20% disease rate in mice that were trans-
planted with K562 cells that were modified to have high levels
of BCR expression (Lin et al., 2001). However, our haploinsuffi-
ciency data do not support an inhibitory role for Bcr expression
in the chronic phase of CML development, as the lower
levels of the Bcr protein together with expression of BCR/ABL
from the knockin allele did not lead to disease (Figures 1D
and 2A).
The BCR/ABL oncogene in the human disease is expressed
not only from the BCR promoter but also from a derivative
t(9;22) Philadelphia chromosome. Epigenetic effects or new
distal enhancers that result from the translocated arm of chro-
mosome 9 may change expression of the oncogene beyond
what is expected from the BCR locus alone. It is therefore
possible that due to a lack of these translocation effects, the level
of BCR/ABL in this knockin mouse model does not perfectly
mimic human disease. Measurements of the levels of BCR/
ABL compared with wild-type BCR in CML cells from patients
in early phases of the disease will help investigators address
the hypothesis that the translocated arm of chromosome 9 leads
to altered expression of the BCR locus.
The lack of hematopoietic neoplasia in the BCR/ABL knockin
mice up to 1.5 years of age contrasts with previous retroviral
and transgenic models using the same human BCR/ABL
cDNA. Prior models demonstrated high penetrance of malig-
nancies between 1 and 4 months of age (Daley et al., 1990; Ele-
fanty et al., 1990; Honda et al., 1998; Huettner et al., 2003;
Jaiswal et al., 2003; Kelliher et al., 1990; Koschmieder et al.,
2005; Voncken et al., 1995; Wong and Witte, 2001). One report
described a transgenic model with somewhat longer disease
latency than the other models (Honda and Hirai, 2001). In this
model with delayed disease, p210 was driven by the promoter
of the tec gene, which is expressed specifically in early hemato-
poietic progenitors, and a total of ten mice were afflicted with
hematopoietic neoplasms between 4 and 12 months of age.
On the other hand, the data from our knockinmice are consistent
with the fact that low levels of BCR/ABL do not confer factor-
independent growth to hematopoietic cell lines (Barnes et al.,
2005), and these findings suggest that the malignancies induced
in prior models may be due, in part, to achievement of very high
levels of BCR/ABL expression. Although there may also be
secondary mutations induced by the prior models (retroviral or
transgene insertional mutagenesis, or genome instability), it
has also been reported that oncogene levels are much higher
in retroviral mouse models than in single-copy oncogene
knockin models (Chen et al., 2008). In fact, BCR/ABL levels
have been reported to increase upon progression from the
chronic phase of the disease to the blast crisis phase (Barnes
et al., 2005; Gaiger et al., 1995). However, the Vav-Cre;BCR/
ABL;AML1/ETO double-knockin mice that developed a myelo-
proliferative disease did not show a large increase in GFP levels.
These data support the assertion that BCR/ABL expression from
theBcr locus is insufficient on its own for development of disease
and requires additional genetic hits that achieve more than just
an increased amount of BCR/ABL.
Unfortunately, genome sequencing experiments to identify
BCR/ABL cooperators have primarily analyzed CML blast crisis
cells rather than cells from the earlier chronic phase of theCell Reports 5, 51–60, October 17, 2013 ª2013 The Authors 57
disease. Recently, pilot exon sequencing and SNP analyses of
the earliest stages of CML have been initiated by a few investiga-
tors (Grossmann et al., 2011; Huh et al., 2011). No frequent
genetic aberrations have yet been reported from these studies.
WT1 and IDH1 mutations have been identified in a few
chronic-phase patients and thus are certainly genes of interest
for examination in the BCR/ABL knockin mouse background.
Because the AML1/ETO mutation has been found in tyrosine-ki-
nase-associated leukemias (Golub et al., 1994; Miyoshi et al.,
1991; Schessl et al., 2005), we generated a group of mice that
were double-mutant BCR/ABL and AML1/ETO knockin alleles,
and did observe a myeloproliferative phenotype. These data
support the idea that additional genetic aberrations are needed
to cooperate with BCR/ABL as a single-copy oncogene to
induce CML.
It remains to be determined whether the BCR/ABL knockin
micewill develop CML and progress to accelerated or frank blast
crisis when combined with additional known genetic stressors
such as expression of Nup98/HoxA9 (Neering et al., 2007),
abnormal IDH1 (Mardis et al., 2009), or deficiencies of TET2
(Moran-Crusio et al., 2011), p53, and/or Ink4a/Arf. Alternatively,
a nonbiased discovery of spontaneous or N-ethyl-N-nitro-
sourea-induced cooperating mutations and other conditions
that promote myeloid leukemogenesis in this mouse model,
such as those that induce the Bcr promoter, will likely shed
new light on the mechanisms of CML development and progres-
sion. The fact that we found no disease in a single BCR/ABL
knockin mouse despite expression of an active oncogene sug-
gests that additional mouse models of other leukemias may pro-
vide new insights into the role(s) of well-known oncogenes in
leukemogenesis. We predict that this conditional knockin model
will be a powerful tool for improving CML prevention in ‘‘previ-
vors’’ with ‘‘normal’’ bone marrow bearing BCR/ABL (Bayraktar
and Goodman, 2010; Biernaux et al., 1995; Bose et al., 1998)
and treatment for individuals in the earliest phases of CML.
EXPERIMENTAL PROCEDURES
Generation of Conditional BCR/ABL Knockin Mice
The targeting vector was constructed to generate a knockin mousemodel that
conditionally expresses BCR/ABL and enhanced GFP (EGFP; Figures 1A and
S1; Extended Experimental Procedures).
Routine Bcr-Abl Genotype Analysis
The Bcr/Abl conditional knockin mice were genotyped from tail snips using
real-time PCR assays designed by Transnetyx. The assays were designed to
detect the wild-type and the mutant alleles in the presence or absence of
the lox-Stop-lox cassette. A PCR assay for GFP was also used to confirm
the presence of the targeted allele.
Transgenic Mice
Double-transgenicMx1-Cre, Vav-Cre, or CMV-Cre;Bcr+/LSL-B/A (Vav-, Mx1-, or
CMV-Cre;B/A) mice were generated by crossing the Bcr+/LSL-B/A mice with
mice transgenic for the Cre transgenes. Mx1-Cre was induced with pIpC
as previously described (Oravecz-Wilson et al., 2009). Triple-transgenic
Vav-Cre;Bcr+/LSL-B/A;Aml+/LSL-A/E mice were generated by crossing Vav-
Cre;Bcr+/LSL-B/A mice with Aml+/LSL-A/E mice (Higuchi et al., 2002). The mice
were housed in the Unit for Laboratory Animal Medicine at the University of
Texas Southwestern Medical Center under specific pathogen-free conditions
and were monitored regularly for evidence of disease and abnormal peripheral
blood cell counts. All mouse experiments were conducted with the approval of58 Cell Reports 5, 51–60, October 17, 2013 ª2013 The Authorsthe UT Southwestern Medical Center Committee on the Use and Care of
Animals.
Drug Treatments
Imatinib treatments were carried out for 2 weeks. Imatinib pills from the hospi-
tal pharmacy were dissolved in water and filtered through a 0.45 mm syringe
filter. The stock concentration was 20 mg/ml (100 ml doses). Mice were given
two doses a day by oral gavage.
Bone Marrow Transplantation and Long-Term Observation
Bone marrow from 6-week-old Creneg;B/A or Vav-Cre;B/A donor mice
(CD45.2) was mixed with bone marrow from PepboyJ BL6 wild-type mice
(CD45.1) prior to retroorbital reconstitution of lethally irradiated recipients.
Each recipient received a 50:50 ratio of CD45.1/CD45.2 bone marrow cells
to allow for subsequent quantitation of donor and recipient chimerism in
transplanted mice. Small cohorts (n = 3) of mice that received Creneg;B/A
and Vav.Cre;B/A bone marrow cells were sacrificed and analyzed at 6,
10, and 16 weeks posttransplantation. The remaining recipients were
preserved for long-term observation (6 months, 1 year, and 1.5 years of
observation).
Hematopoietic Analysis
Peripheral blood, spleen, and bone marrow cells were analyzed for lineage
(CD3, B220, Mac-GR1), progenitor (lin-,Sca-,c-kit+, CD16/32+), and HSC
(lin, Sca+, CD150+) markers using the LSR Fortessa flow cytometer (BD).
A complete blood count (CBC) analysis was performed on peripheral blood
using the Hemavet 950 with MULTI-TROL Mouse as an equilibration control
(Drew Scientific).
Western Blot and Immunoprecipitation
Mouse tissues were solubilized by extraction in 13 RIPA lysis buffer (Cell
Signaling Technology), electrophoresed on 6% SDS-PAGE gels, and trans-
ferred to a polyvinylidene fluoride membrane. Proteins were detected using
affinity-purified BCR antiserum (Cell Signaling Technology) or anti c-Abl anti-
serum (Cell Signaling Technology) and visualized using Supersignal West
Pico chemiluminescence substrate (Pierce). Immunoprecipitation of solubi-
lized brain and spleen extracts was performed using anti c-Abl antiserum after
extracts were precleared with protein G-Sepharose. Immune complexes were
washed with 13 RIPA lysis buffer, analyzed by SDS-PAGE, and blotted as
indicated.
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